Overview

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of 6-month administration of CP-945,598 on: - weight loss and waist circumference, - blood pressure, cholesterol, glucose - other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α and hsCRP - the relationship between the concentration of the drug on the blood and the above parameters - physical and psychosocial functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Sibutramine